Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Share-based Compensation (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Share-based Compensation for 11 consecutive years, with $2000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 102.78% to $2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96000.0 through Dec 2025, down 91.02% year-over-year, with the annual reading at $96000.0 for FY2025, 91.02% down from the prior year.
  • Share-based Compensation hit $2000.0 in Q4 2025 for Aptevo Therapeutics, down from $77000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $915000.0 in Q1 2023 to a low of -$163000.0 in Q2 2025.
  • Historically, Share-based Compensation has averaged $340150.0 across 5 years, with a median of $357500.0 in 2022.
  • Biggest YoY gain for Share-based Compensation was 102.78% in 2025; the steepest drop was 159.71% in 2025.
  • Year by year, Share-based Compensation stood at $179000.0 in 2021, then skyrocketed by 99.44% to $357000.0 in 2022, then grew by 0.28% to $358000.0 in 2023, then plummeted by 120.11% to -$72000.0 in 2024, then skyrocketed by 102.78% to $2000.0 in 2025.
  • Business Quant data shows Share-based Compensation for APVO at $2000.0 in Q4 2025, $77000.0 in Q3 2025, and -$163000.0 in Q2 2025.